


## Westminster Health Forum policy conference:

### Next steps for AI use in life sciences

Timing: Morning, Tuesday, 14<sup>th</sup> July 2026

\*\*\*Taking Place Online\*\*\*



WESTMINSTER  
HEALTH FORUM

Draft agenda subject to change

- 8.30 Registration
- 9.00 **Chair's opening remarks**  
Senior Parliamentarian
- 9.05 **Assessing the National Commission's recommendations on AI regulation in healthcare**  
**Professor Alastair Denniston**, Chair, UK National Commission on the Regulation of AI in Healthcare  
Questions and comments from the floor
- 9.30 **Addressing barriers to AI in life sciences - data access, responsible use, and risk mitigation**  
*data consistency, quality and interoperability | alignment of datasets for use in AI research and development | AI-ready data infrastructure and the role of the HDRS | access models, timelines and cost considerations for SMEs and academic teams | risk management, including hallucinations, bias, and data misuse | standards for synthetic data and RAG systems | AI assurance and validation mechanisms | maintaining patient safety and trust | consent frameworks, public engagement, and ethical standards*  
**Taly Dvorkis**, Director, Fieldfisher  
**Susheel Varma**, Chief Data Officer, Sage Bionetworks  
Senior representative, research  
Senior representative, SME  
Senior representative, public engagement
- 9.55 Questions and comments from the floor
- 10.15 **Regulatory pathways for accelerating safe adoption of AI in life sciences - insights from the AI Airlock sandbox**  
**MiRa Jacobs**, Head, Digital Health, Innovative Devices Team, and Agency Lead, AI Airlock, Medicines and Healthcare products Regulatory Agency
- 10.40 **Chair's closing remarks**  
Senior Parliamentarian
- 10.45 Break
- 10.55 **Chair's opening remarks**  
Senior Parliamentarian
- 11.00 **Key considerations for scaling up and adoption of AI in research and drug discovery**  
*transition from trials to broader deployment | digital integration and evidence standards to support evaluation and wider access | future use of bespoke IT solutions | regulator, industry, and research collaboration | governance frameworks for clinical and research deployment | workforce development | clinical capability, adoption readiness, and sustainable deployment | defining minimum standards for clinical deployment | clarifying allocation of liability across clinical contexts | ongoing monitoring and real-world evaluation | reliability of AI ambient scribes and AI as a medical device*  
**Dr Kristin-Anne Rutter**, Executive Director, Cambridge University Health Partners  
Senior representative, research  
Senior representative, industry  
Questions and comments from the floor
- 11.35 **International pathways for accelerating access to breakthrough technologies**  
**Junaid Bajwa**, Senior Partner, Head, UK, and Science Partner, Pioneering Intelligence, Flagship Pioneering
- 11.45 **Priorities for investment, commercialisation and market access**  
*stage-specific investment requirements | establishing clear pathways for commercial adoption | improving regulatory predictability to support investment decisions | Regulatory Innovation Corridor priorities | entry points and eligibility | achieving regulatory coherence | alignment with UKRI AI Research and Innovation Strategic Framework priorities | managing uncertainty around commercial outcomes and system performance | procurement approaches | assessing data readiness gaps | opportunities for cross-border collaboration | reimbursement and procurement barriers*  
Senior representative, health partnerships  
Senior representative, investment  
Senior representative, NHS trust  
  
Questions and comments from the floor
- 12.30 **Next steps for AI and life sciences**  
Senior representative, healthcare policy  
Questions and comments from the floor
- 12.55 **Chair's and Westminster Health Forum closing remarks**  
Senior Parliamentarian  
**Jessica Lear**, Westminster Health Forum